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Abstract
Background: Schistosomiasis is a kind of parasitic zoonoses which causes serious damage to public health and
social development. China is one of the countries most affected by Schistosoma japonicum and an effective vaccine
is still needed. In this study, we adopted Tat-mediated protein transduction technology to investigate the impact of
different antigen presented approaches on host’s immune response and the potential protection against
Schistosoma japonicum infection.
Results: We successfully constructed the recombinant S. japonicum triosephosphate isomerase, Tat-TPI, as a vaccine
candidate. Whether injected with Tat-TPI in foot pad or vaccinated with Tat-TPI in the back subcutaneously for
three times, the draining popliteal lymph nodes and spleen both developed a stronger CD8+T response (Tc1) in
mice. Not only that, but it also helped CD4+T cells to produce more IFN-γ than TPI immunisation. In addition, it
could boost IgG production, especially IgG1 subclass. Most importantly, Tat-TPI immunisation led to the significant
smaller area of a single egg granuloma in the livers as compared with TPI-vaccinated or control groups. However,
the anti-infection efficiency induced by Tat-TPI was still restricted.
Conclusion: This study indicated that immunisation with Tat-fused TPI could contribute to enhance CD4+T-cell
response and decrease hepatic egg granulomatous area after S. japonicum infection though it did not achieve our
expected protection against Schistosoma japonicum infection. The optimal vaccine strategy warrants further research.
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Background
Schistosomiasis is still a significant public health prob-
lem in tropical and subtropical regions [1]. Although in
the past six decades, a series of comprehensive measures
have been adopted to control schistosomiasis japonica in
China, there remain many challenges we need to face.
According to conservative estimates, about 0.29 million
people are infected and more than 240 million people
living in 180 counties remain endemic for S. japonicum
in China today [2]. Transmitted by Oncomelania hupensis,
S. japonicum could cause serious pathology damage to the
liver and intestine. Praziquantel is the effective drug for
treatment, but it does not prevent post-treatment reinfec-
tion and long-term application might lead to increase the
drug resistance [3, 4]. Some other measures including
environmental and health-care management and snail
control have achieved great success in controlling, but the
factors of reinfection, such as many reservoir hosts, still
exist [5]. Therefore, development of safe and effective
vaccines, especially for veterinary use, is a high priority.
The radiation-attenuated (RA) vaccine can induce high
protection against schistosome infection in many experi-
mental animal models [6, 7]. However, the requirement
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of large amounts of cercariae, potential side effects and
the risk of reinfection limited its application in the
population. Our previous experiments showed that three
vaccinations with RA cercariae could induce high levels
of worm reduction rate (77.62 %) and hepatic egg reduc-
tion rate (88.8 %) in pigs [7]. In this case, antibody and
CD4+T-cell-mediated, IFN-γ-dependent effector mech-
anisms are the important reason for high protection
[8–10]. We also found that about one week after
immunisation with RA cercariae, some gene expression
of killer factors like granzymes and IFN-γ was en-
hanced in the skin draining lymph nodes. This implies
that CD8+T-cells might be related to radiation-induced
high protection. Similarly, Pancré et al. found that CTL
response caused by CD8+T-cells could participate in
the protection mechanism against S. mansoni infection
[11, 12]. Thus, we expect that the cooperation between
CD8+T cells, CD4+T cells and IgG responses would
achieve an effective protection against schistosomiasis.
Triosephosphate isomerase (TPI) is one of the World
Health Organisation (WHO) recommended schistosome
vaccine candidate molecules. It is a kind of glycolytic
enzyme, involved in the process of glucose metabolism
[13]. TPI is distributed in all developmental stages of
schistosome life-cycle. It was reported that SjTPI immu-
nised mice together with Freund's adjuvant induce a
57.8 % liver egg reduction rate [14], while DNA vaccines
containing the optimised SjTPI gene (SjTPI.opt) was
able to induce 36–39 % reductions in worm burden
[13, 15]. Protein transduction domain (PTDs), also
known as cell-permeable peptides (CPPs), refers to a
class of small (<20 amino acids), relatively nontoxic
peptides, which are capable of not only crossing the cell
membrane themselves but also carrying many various
small molecules into cells, including siRNA, plasmid
DNA, combinant proteins, viruses and other different
nanoparticles [16]. Tat, the HIV transactivator of tran-
scription protein, is the most widely used PTDs. Tat-fused
protein could efficiently transduce dendritic cells
(DCs) and was processed by proteasomes for MHC
class I-dependent presentation to CD8+T lymphocytes
[17]. In this study, we evaluated the immunogenicity
and efficacy of the fusion protein containing the
protein transduction domain of HIV-1 TAT and the
Schistosoma japonicum antigen Sj-TPI in a mouse
model. The approach we used was to express this
fused antigen to facilitate the entry of protein into
cells and enhance CD4+ and CD8+ T-cell response.
Methods
Ethics statement
The animal experiments were approved by the Nanjing
Medical University Animal Ethics Committee. All the
mice were subjected to minimum suffering.
Animals and parasites
Female BALB/c mice, 6–8 week-old, were obtained from
Comparative Medicine Center of Yangzhou University
(Yangzhou, China) and kept in specific pathogen-free
environment for experimental use. Snails infected with
Schistosoma japonicum (a Chinese strain of S. japonicum-
infected Oncomelania hupensis) were purchased from the
Jiangsu Institute of Parasitic Diseases (Wuxi, China).
Cercariae were collected from infected snails.
Prokaryotic expression vector construction and
expression of the fusion protein Tat-TPI and TPI
The plasmid, pcDNA3.1-SjTPI.opt [15, 18], containing the
optimised triosephosphate isomerase gene of S. japonicum,
was provided by the Jiangsu Institute of Parasitic Diseases
(Wuxi, China). Then according to the nucleic acid
sequences of Tat-TPI and TPI, the following primers
were designed: (i) Tat-TPI: forward primer: 5’-CGC
GGA TCC TAT GGC AGG AAG AAG CGG AGA
CAG CGA CGA AGA AGC AGC AGC CGG AAG
TT-3’; (ii) TPI, forward primer: 5’-CGC GGA TCC
AGC AGC AGC CGG AAG TT-3’; (iii) reverse primers
for Tat-TPI and TPI: 5’-CCC AAG CTT TCA CTG
CCG GGC CTT G-3’. The gene fragments of Tat-TPI
and TPI were amplified by PCR. These two genes were
respectively cloned into the His-tagged protein downstream
of expression vector pET-32a(+) and the recombinant plas-
mids pET-32a(+)-Tat-TPI and pET-32a(+)-TPI were ob-
tained. The recombinant plasmids were transformed into E.
coli strain BMRosetta (DE3) for protein expression. After
induced expression by IPTG for 4 h at 25 °C and subse-
quent purification with Ni-NTA Sepharose FF, the purified
fusion protein Tat-TPI and TPI were obtained.
Immune reaction of the draining lymph nodes
To ascertain the immune response induced by TAT-
coupled protein in mice, mouse foot pads of each group
were injected subcutaneously with 50 μg Tat-TPI, TPI in
20 μl PBS per side, respectively. Negative controls were
injected with isometric PBS. The draining popliteal lymph
nodes were aseptically removed 4 days after vaccination,
then lymphocytes were prepared for flow cytometry detec-
tion. The experiments were duplicated twice.
Antibody-blocking assay
In order to understand the effect of CD8+T cells on
CD4+T-cell response, we performed antibody blocking
experiments in vitro. The single spleen cell suspensions
were incubated in 24-well flat-bottom plates (1 ml/well,
2 × 106 cells/ml). For CD8+T cells blocking experiments,
spleen T cells were treated with 5 mg/ml of anti-mouse
CD8a antibody (BioLegend, 100735, Canada) or isotype
control antibody IgG2a for 1 h at 37 °C. Then Tat-TPI,
TPI (100 mg/ml) and PBS were added, respectively, and
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incubated at 37 °C, 5 % CO2. After 18 h incubation, T cells
were restimulated for 6 h at 37 °C in 5 % CO2 with 2 μl
Leukocyte Activation Cocktail (BD Biosciences). Finally,
cells were collected for flow cytometry detection of Th1
expression. The experiments were repeated four times.
Animal immunisation and challenge experiment
Mice were randomly divided into four groups (20 mice/
group). The antigens Tat-TPI and TPI were administered
subcutaneously (100 μg/mice) emulsified in the same
volume of incomplete Freund’s adjuvant (IFA) per mouse
in corresponding groups on days 1, 14 and 28. The other
two groups were injected isopyknic IFA and PBS with the
same immune process. Two weeks after the third immun-
isation, eight mice in each group were sacrificed for flow
cytometry assay and serum samples were collected for anti-
body analysis. The remaining mice were percutaneously
challenged with 40 ± 1 S. japonicum cercariae. All animals
were sacrificed at 6 weeks post-infection and parasite
burden, T-cell responses were observed. Parasite burden
was evaluated by adult worm recovery, egg burdens and
area of single egg granuloma in the livers. Briefly, the adult
worms were collected and counted after perfusion of the
portal vein with PBS. Meanwhile, the liver was isolated,
weighed and digested with 10 ml 5 % KOH at 37 °C for
24 h and eggs counted in 10 μl liver digest solution. Each
liver sample was counted 3 times and the mean count was
used as eggs per gram (EPG) in mice. The sectioned liver
tissue (1–5 cm3) were fixed in 4 % paraformaldehyde,
embedded in paraffin and stained with haematoxilin and
eosin, according to standard protocols. Single-egg granu-
lomas were examined and their sizes were calculated using
AxioVision Rel 4.7 (Carl Zeiss GmbH, Jena, Germany). At
least fifteen single egg granulomas per liver section were
photographed. Additionally, the percentage of Th1 and Tc1
in the spleens was detected by flow cytometry.
Measurement of specific antibodies response
ELISA was applied to detect schistosome-specific antibody
responses. Briefly, 96-well plates (Costar) were coated with
TPI (10 μg/ml) at 4 °C overnight, then washed 5 times
with PBS-0.05 % Tween-20 (PBST) and blocked in PBST-
5 % skimmed milk at 37 °C for 2 h. After washing 5 times
again, each well was incubated with 100 μl sera samples
diluted 1:100 with PBS for 2 h at 37 °C. Next, plates were
washed with PBST and incubated with 100 μl HRP-
conjugated goat-anti-mouse IgG, IgG1 and IgG2a (diluted
1:5000, Biosharp) for 1 h at 37 °C. Lastly, after five washes
with PBST, each well plate was developed with 100 μl tet-
ramethylbenzidine (TMB, 10 mg/ml) for 20 min at 37 °C
and the reaction was stopped by adding 50 μl H2SO4
(2 M). The optical density (OD) was read at 450 nm using
an ELISA reader (Bio-TEK, USA).
Flow cytometry detection
Flow cytometry was used to analyse the percentages of
Th1, Th2, Tc1, Tc2 in the draining popliteal lymph nodes
or spleens after immunisation or infection ex vivo and in
vitro CD8+T cell-blocking experiment. Single cell
suspensions were prepared by collecting the cells after
anti-CD8 antibody blocking, or grinding popliteal lymph
nodes or spleens in incomplete RPMI 1 × 1640 medium
(WISENT, Canada) followed by red blood cell (RBC) lysis,
then 2 × 106 cells per ml were stimulated for 6 h at 37 °C
in 5 % CO2 with 2 μl Leukocyte Activation Cocktail with
BD GolgiPlug (BD Biosciences, USA) in 24-well plates
(1 ml/well). Next, 1 × 106 cells were stained in 100 μl of
Staining Buffer [PBS containing 1 % FBS (Gibco, USA)]
with following fluorochrome-conjugated monoclonal
Fig. 1 Expression, purification and identification of the fusion proteins Tat-TPI and TPI. a. Purification of two fusion proteins detected by
Protein Gel Electrophoresis. M: molecular weight marker, Lane 1: recombinant SjTat-TPI, Lane 2: recombinant SjTPI, Lane 3: the recombinant
plasmid without purification. b. Fusion proteins recognised by His-Ab with Western blotting. Lane 1: recombinant SjTat-TPI, Lane 2: recombinant SjTPI.
c. Fusion proteins recognised by S. japonicum infected-mice serum with Western blotting. Lane 1: recombinant SjTat-TPI, Lane 2: recombinant SjTPI
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antibodies specific for surface antigen: CD3e-APC (BD
Biosciences), CD4-FITC (BD Biosciences), CD8a-FITC
(BD Biosciences), APC-labelled Hamster IgG1 (BD Biosci-
ences) and FITC-labeled Rat IgG2a isotype control anti-
bodies (BD Biosciences) for 30 min at 4 °C in the dark.
The cells were washed twice with Staining Buffer, then
fixed and permeabilised with Cytofix/Cytoperm Fixation/
Permeabilisation Solution Kit (BD Biosciences) following
the manufacturer’s instructions. Subsequently, cells were
incubated for 30 min at 4 °C in the dark with the following
monoclonal antibodies: IFN-γ-PE (BD Biosciences), IL-
4-PE (BD Biosciences) and PE-labeled Rat IgG1 isotype
control antibody (BD Biosciences). Finally, cells were
washed twice with 1 × Perm/Wash buffer (BD Biosciences)
and resuspended in Staining Buffer prior to flow cy-
tometry analysis.
Statistics
Differences between groups were analysed by one-way
analysis of variance (ANOVA) using GraphPad Prism
version 5.01 for Windows. Significance was considered
when P values ≤ 0.05 or 0.01.
Results
Production and characterisation of recombinant Tat-TPI
and TPI proteins
After PCR amplification, we obtained the gene fragment
of T-TPI (about 807 bp long), slightly longer than the
Fig. 2 Immune responses in the draining popliteal lymph nodes of mice induced by Tat-TPI (T-TPI) and TPI proteins. a and c. Percentages of
CD4+IFN-γ+ cells (Th1), CD8+IFN-γ+ cells (Tc1) analysed by FACS. b. The ratio of CD4+ T cells to CD8+ T cells (CD4/CD8) in the draining popliteal lymph
nodes. Data are presented as the means ± SEM from six mice in each group. (*P < 0.05; **P < 0.01)
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TPI fragment. The recombinant plasmids were constructed
successfully, and the recombinant proteins were purified to
obtain fusion protein. By SDS-PAGE electrophoresis, the
protein bands appeared at about 46 kDa. The fusion pro-
teins of T-TPI and TPI were also recognised by His-Ab and
S. japonicum infected-mice serum respectively in Western
blotting (Fig. 1).
Immune response in the draining popliteal lymph nodes
To investigate the immune effect induced by Tat-TPI
and TPI, we injected these two proteins to mice footpad
respectively, and observed T-cell response in the drain-
ing popliteal lymph nodes. On day 4 post injection, Tat-
TPI and TPI vaccination can both evoke host’s immune
response. The results showed that Tat-TPI and TPI
immunisation in foot pad of mice could induce higher
levels Tc1 response in the draining popliteal lymph
nodes compared to PBS controls (P < 0.01). More
importantly, CD4+IFN-γ+ T-cell response could be
quickly evoked by Tat-TPI instead of TPI. There was a
significant difference in Tat-TPI- and TPI-vaccinated
groups on CD4+IFN-γ+ T-cell percentages in the poplit-
eal lymph nodes (P < 0.05) but not on CD8+IFN-γ+ T-
cell percentages (Fig. 2a, and c).
CD8+ T cells-blocking experiment
To ascertain if CD8+ T cells could help Th1 response,
we used anti-mouse CD8a antibody to block CD8+ T
cells. Flow cytometry showed Tat-TPI stimulated spleno-
cytes produced higher CD3+CD4+IFN-γ+ cells than TPI
stimulation. When CD8+ T cells were blocked (Fig. 3a),
there was no significant influence on the percentages of
CD4+IFN-γ+ T cells in splenocytes with TPI and PBS
stimulation; however, T-TPI stimulated spleen cells
expressed lower levels of CD4+ IFN-γ+ cells than those
without CD8+ T-cell blockage (P < 0.05) (Fig. 3b, and c).
Fig. 3 Th1 immune response after CD8+T cells blockage in vitro. a. CD3+CD8+T cells were successfully blocked. The blocking efficiency was more
than 99.6 %. b, c. Percentages of CD4+IFN-γ+ (Th1) in Tat-TPI (T-TPI), TPI stimulated splenocytes with or without CD8+T-cell blockage. Data are
presented as the means ± SEM from four independent experiments. (*P < 0.05; **P < 0.01)
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A high T-cell and antibody response induced by Tat-TPI
before challenge
In the conventional vaccination-challenge experiment,
three immunisations with antigen are usually adopted.
To assess the impact of Tat-coupled TPI vaccination on
the immune system in mice, we analysed the percentages
of CD4+IFN-γ+(Th1), CD8+IFN-γ+(Tc1) T cells in the
spleens by flow cytometry. Results showed that the
percentages of CD4+IFN-γ+ and CD8+IFN-γ+ T cells
from IFA-immunised mice were similar to those in
PBS controls, while both of them were increased sig-
nificantly in Tat-TPI-immunised and TPI-immunised
mice (P < 0.01). Moreover, we found that CD4+IFN-γ+ T-
cell percentages were even higher in Tat-TPI group com-
pared to TPI group (P < 0.05) (Fig. 4a, and b). These
findings suggested that Tat-TPI immunisation could elicit a
higher level of Th1 and Tc1 response at the same time.
Antibody responses including IgG, IgG1 and IgG2a
antibody levels assayed by ELISA were also observed in
addition to T-cell responses at two weeks after the third
vaccination prior to challenge. High levels of IgG, IgG1
and IgG2a antibodies were detected in sera from mice
vaccinated with Tat-TPI and TPI in comparison to IFA
immunisation and PBS control (P < 0.01) (Fig. 4c). Both
Tat-TPI and TPI immunisation elicited a strong IgG
response in mice with little difference in IgG levels
between them. However, there were apparent differences
in IgG1 and IgG2a levels based on their OD values.
Three immunisations with Tat-TPI produced more IgG1
than TPI immunisation (P < 0.05), while the opposite
trend was seen in the IgG2a production (P < 0.01). The
ratio of IgG2a/IgG1 in mice vaccinated with Tat-TPI and
TPI were 0.63 and 1.59, respectively.
Immune protection associated with Tat-TPI and TPI
vaccination
At six weeks after S. japonicum cercariae challenge, we
calculated the numbers of adult worm recovered and eggs
in the livers. Although the numbers of adult worms and
eggs per gram (EPG) in the livers of mice vaccinated with
TPI or Tat-TPI were slightly less than those in IFA im-
munisation and PBS control, there showed no significant
differences among these four groups. Most importantly,
these two antigens immunisation led to the smaller hep-
atic granuloma area with a single egg than IFA or PBS
control groups with a significant difference. Especially,
Tat-TPI-immunised mice showed the smallest granuloma
area in the liver among the four groups (Fig. 5c, and d).
The Th1 and Tc1 responses were detected by flow cytom-
etry (Fig. 5e, and f). High levels of Th1 and Tc1 responses
Fig. 4 T cell and antibodies responses after three immunisations with T-TPI + IFA, TPI + IFA, IFA and PBS. a and b: Percentages of CD3+CD4+IFN-γ+
(Th1) and CD3+CD8+IFN-γ+ (Tc1) gated from CD3+ cells analysed by FACS. c. IgG, IgG1 and IgG2a levels in mice sera were detected. Data are
presented as the means ± SEM from eight mice in each group. (*P < 0.05; **P < 0.01)
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were detected in mice immunised with Tat-TPI and TPI
in comparison to IFA immunisation and PBS control
(P < 0.01). Results also showed that Th1 and Tc1 re-
sponses in mice immunised with TPI remained at high
levels, which were still slightly lower than those of Tat-
TPI-immunised mice, but there was no statistical sig-
nificance in Tc1 reaction.
Discussion
In this study, our initial conception was that the optimal
cooperation among CD8+T cells, CD4+T cells and antibody
responses would be required against schistosome infection.
Thus, we adopted the protein transduction technology by
using cell-permeable peptides to investigate the impact of
different antigen-presented approaches on the host im-
mune response and anti-infection protection.
The 11aa HIV-1 Tat was used to construct the fusion
protein, Tat-TPI, in our study. HIV-Tat can activate CD8
+T cells to produce high levels of IFN-γ. This concept is
supported by some other results. Kronenberg et al. [19]
reported that Tat-fusion proteins are superior in activat-
ing protective, CD8+T-cell response against Leishmania
major when compared with antigen alone, and similar
results were reported by Nicoli et al. [20] and Sforza et
al. [21]. The increased CD8+T cells proliferation may be
related to the improved expression of MHC-I complexes
on the surface of DCs stimulated by Tat [22, 23]. Tat
modulates the expression of T-box transcription factors
T-bet [21] critical for stimulation of T-lymphocytes. In
addition, it has been demonstrated that Tat could in-
crease the secretion of IFN-α by macrophages [24] and
IL-12 by DCs [25]. Our study showed that whether
injected with Tat-TPI in foot pad or vaccinated with Tat-
TPI in the back subcutaneously for three times, the
draining lymph nodes and spleen both developed stron-
ger CD8+T responses (Tc1) in the host.
It is the noteworthy finding that a higher Th1 level
was observed in Tat-TPI vaccinated group in comparison
to TPI immunisation. In order to better understand
\whether the increased Th1 response was influenced by
CD8+ T cells, we conducted anti-CD8a antibody-blocking
assay in vitro. When CD8+T cells were blocked, Tat-TPI
stimulated spleen cells expressed significantly lower levels
of Th1 cells, indicating that CD8+T cells may assist CD4+T
cells to produce more IFN-γ (Th1), which was in accord-
ance with the study of Herath et al. [26]. CD8+T cells pro-
ducing IFN-γ are important for regulating the CD4+T-cell
response and Herath et al. [26] observed that the percent-
age of CD4+T cells producing IFN-γ was reduced with
the depletion of CD8+T cells. In human leishmaniasis,
da Silva Santos et al. [27] also found that CD8+T cells
expressed activation markers at first and drove Th1 dif-
ferentiation. On the other hand, CD8+T cells could also
regulate IgG1 production [28]. We did realise that
Fig. 5 Parasite burden and immune response were observed at 6 weeks after S. japonicum infection in mice vaccinated with T-TPI + IFA, TPI + IFA, IFA and
PBS. a. Average number of worms recovered. b. Average number of eggs per gram (EPG) in the liver. c. Representative granulomas with a single egg from
each group (100×). d. Average area of single egg granulomas from each group. e, f. Percentages of CD3+CD4+IFN-γ+(Th1) and CD3+CD8+IFN-γ+(Tc1) gated
from CD3+ T cells analysed by FACS. Each bar represents the means ± SEM from twelve mice per group. (*P< 0.05; **P< 0.01)
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immunisation with Tat-TPI for three times was prone
to produce IgG1 antibody subtype, while TPI vaccin-
ation was predominant to induce IgG2a production. In
schistosome infection, IgG2a subclass is considered to
be related to high protection [7, 29].
Generally, the studies of protective mechanisms against
schistosomiasis are concentrated on CD4+T cells and anti-
body responses [6]. First, CD4+T-cell-produced IFN-γ is
considered as the key factor [30, 31]. IFN-γ activates host
macrophages to produce NO, which help eliminate para-
sites efficiently [10] . Secondly, the antibody response in
attenuated vaccine-induced protection has been given
much attention [9]. Yole et al. [32] reported that schisto-
some specific IgG antibody levels were positively correlated
with the protection level against S. mansoni infection. How-
ever, the role of CD8+T cells played in schistosome infec-
tion, has been debated. In our study, we found that the
increased CD8+T-cell response (Tc1) induced by Tat-TPI
could not affect the development of adult worms, but helps
to reduce significantly the hepatic granulomatous area with
a single egg. Previous studies [33, 34] have shown that
granulomatous reactions were gradually down-regulated
due to the increase of CD8+T cells in the chronic phase of
Schistosoma mansoni infection and the new granuloma
formations were decreased significantly at 16–20 weeks
after infection. When the spleen and lymph node cells of
chronic phase were transferred to acute infection mice,
newly formed granulomas in mice reduced significantly,
and the inhibitory effect against granuloma response
would disappear after depletion of CD8+T cells. Thus,
in schistosome infection, CD8+T cells might regulate
the immune pathological reaction via secreting some
cytokines such as IFN-γ. Although high levels of Th1,
Tc1 and IgG were induced by Tat-TPI immunisation,
they did not achieve the ideal reduction rate of worm
(11.9 %) and egg (12.4 %) burden in mice, being even
lower than those in the TPI immunised group (21.9 %
and 12.6 %, respectively). We have to admit that the
protective mechanisms against schistosome infection
are so complicated that we need to further explore the
optimal vaccine strategy. Another possible cause is that
mice model is not an ideal animal model to test vaccine
efficacy, but is convenient to provide the relevant
immunological observations.
In summary, this study suggests that immunisation
with Tat-fused TPI may contribute to enhance CD4+ T-
cell response and decrease hepatic egg granulomatous
area after S. japonicum infection, but the anti-infection
efficiency was limited. Thus, the optimal vaccine strategy
is still the goal we are pursuing.
Conclusions
Tat-coupled TPI immunisation could activate CD8+T
cells in mice, which assist CD4+T cells to produce more
IFN-γ. Also, it could boost IgG production, especially
IgG1 subclass. Although this vaccine strategy with Tat-
TPI immunisation did not turn out to be effective in de-
creasing parasite burden, it did reduce the single egg
granuloma area in the livers after Schistosoma japonicum
infection.
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